



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Murine Anti-Factor VIII

Clone GMA-8011

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca^{2+} . Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8011 (also known as 2A9)¹ recognizes the C1 domain of FVIII, inhibits FVIII activation and binding to VWF and phospholipids², and displays subnanomolar binding to FVIII by surface plasmon resonance².

Description

Antibody Source:	mouse monoclonal, IgG _{2a}
Antigen Species Bound:	human
Specificity:	FVIII C1 domain (residues 2157-2164, 2091-2092) ²
Immunogen:	B-domain deleted recombinant human FVIII

Formulation and Storage

Purity:	Purified by protein G affinity chromatography from serum-free cell culture supernatant.
Product Formulation:	Lyophilized from a ≥ 1 mg/ml solution in 20 mM NaH_2PO_4 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 ($\epsilon_{0.1\%}$).
Reconstitution:	Reconstitute with deionized water.
Storage:	Store lyophilized or reconstituted and aliquoted material at -20°C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4°C .
Country of origin:	USA
Size Options:	0.1 mg or 0.5 mg

Applications

Working Concentration:	Approximately 1-5 $\mu\text{g/ml}$. Researcher should titer antibody in specific assay.
ELISA:	Binds immobilized human FVIII.
Immunoblotting:	Not recommended.
Inhibition:	Weakly inhibitory in Bethesda assay ² .
Affinity Constant (apparent K_D):	$K_D = 0.9$ nM, ($k_{\text{dis}} = 2.2 \times 10^{-4}$ sec ⁻¹) ²

References

- [1] R.J. Summers, S.L. Meeks, J.F. Healey, H.C. Brown, E.T. Parker, C.L. Kempton, C.B. Doering, P. Lollar. Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. (2011). *Blood*. 117(11):3190-3198.
- [2] G. Batsuli, W. Deng, J.F. Healey, E.T. Parker, W. H. Baldwin, C. Cox, B. Nguyen, J. Kahle, C. Konigs, R. Li, P. Lollar, S.L. Meeks. High affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. (2016). *Blood*. 128(16):2055-2067.
- [3] J.M. Stewart, A.F. Tarantal, W.J. Hawthorne, E.J. Salvaris, P.J. O'Connell, M.B. Nottle, A.J.F. d'Apice, P.J. Cowan, M. Kearns-Jonker. Rhesus monkeys and baboons develop factor VIII inhibitors in response to porcine endothelial cells or islets. (2014). *Xenotransplantation*. 21(4):341-352.
- [4] M.A. Zimmermann, J. Oldenburg, C.R. Muller, S. Rost. Expression Studies of Mutant Factor VIII Alleles With Premature Termination Codons With Regard to Inhibitor Formation. (2014). *Haemophilia*. 20(3):e215-e221.
- [5] J. Kahle, A. Orłowski, D. Stichel, J.F. Healey, E.T. Parker, M. Jacquemin, M. Krause, A. Tiede, D. Schwabe, P. Lollar, C. Königs. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. (2017). *Blood*. 130(6):808-816.
- [6] S. Krishnamoorthy, T. Liu, D. Drager, S.Patarroyo-White, E.S. Chhabra, R. Peters, N. Josephson, D. Lillicrap, R.S. Blumberg, G.F. Pierce, H. Jiang. (2016). Recombinant factor VIII Fc (rFVIII-Fc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. *Cell Immunol*. 301:30-39.

For in vitro research only. Not for use as a diagnostic or therapeutic. All sales governed by Warranty Policy located at: <https://greenmoab.com/about-gma/warranty-policy/>